Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Zoetis Q3 Beat Trims 2026 Guidance; Longer-Term Upside From 2027–2028 Launches

Nov 5, 2026, 1:41 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Fundamental beat and guidance raise imply earnings power and potential multiple expansion; near-term weakness appears sentiment-driven.

AI summary

What happened, with direct paths to the underlying reporting

Zoetis topped Q3 expectations with EPS of $1.75 on $2.391B revenue, beating estimates. U.S. Companion Animal weakness offset by Livestock and Diagnostics growth. The company raised its 2026 adjusted EPS to $6.25-$6.35 and 2026 sales to $9.22B-$9.32B, signaling confidence despite ongoing vet-visit and price-headwinds. Shares fell about 6% on the results, with longer-term upside tied to 2027-2028 launches.

Q3 adjusted EPS $1.75 beat consensus $1.51.
Sales $2.391B beat consensus $2.304B.
U.S. revenue $1.2B down 6% YoY.
Companion Animal down 8%; Livestock up 5%.
2026 guidance raised: EPS $6.25-$6.35; sales $9.22B-$9.32B.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.